Cel Sci (CVM) Non-Current Assets (2010 - 2026)
Cel Sci (CVM) posted Non-Current Assets of $14.8 million for Q1 2026, down 6.63% sequentially from $15.9 million in Q4 2025, and down 21.14% YoY from $18.8 million in Q1 2025.
Cel Sci (CVM) Non-Current Assets (2010 - 2026) Analysis & Trends
Cel Sci has reported Non-Current Assets for 16 years, with the latest figure at $14.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 21.14% year-over-year to $14.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.0 million (down 18.9% YoY) and the FY2025 annual result came in at $16.6 million, down 20.9% from the prior year.
- Non-Current Assets slipped to $14.8 million in Q1 2026 per CVM's latest filing, from $15.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $26.9 million in Q1 2022 and troughed at $14.8 million in Q1 2026.
- A 5-year average of $21.5 million and a median of $21.5 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 1481.51% in 2022, then dropped 21.14% in 2026.
- Over 5 years, Non-Current Assets stood at $24.2 million in 2022, then slipped by 6.61% to $22.6 million in 2023, then slipped by 12.04% to $19.8 million in 2024, then slipped by 20.04% to $15.9 million in 2025, then declined by 6.63% to $14.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $14.8 million, $15.9 million, and $16.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 13.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.81 Mn |
| Dec 31, 2025 | 15.86 Mn |
| Sep 30, 2025 | 16.56 Mn |
| Jun 30, 2025 | 17.71 Mn |
| Mar 31, 2025 | 18.78 Mn |
| Dec 31, 2024 | 19.84 Mn |
| Sep 30, 2024 | 20.94 Mn |
| Jun 30, 2024 | 20.53 Mn |
| Mar 31, 2024 | 21.54 Mn |
| Dec 31, 2023 | 22.56 Mn |
| Sep 30, 2023 | 23.61 Mn |
| Jun 30, 2023 | 24.59 Mn |
| Mar 31, 2023 | 25.62 Mn |
| Dec 31, 2022 | 24.15 Mn |
| Sep 30, 2022 | 25.09 Mn |
| Jun 30, 2022 | 25.93 Mn |
| Mar 31, 2022 | 26.89 Mn |
| Dec 31, 2021 | 27.80 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Jun 30, 2021 | 1.90 Mn |